<p>MiMedx Group（纳斯达克代码：MDXG - 获取免费报告）在周三发布给投资者的报告中，被 StockNews.com 的研究分析师将评级从 “强力买入” 下调至 “买入”。</p>
<p>另外，Cantor Fitzgerald 在 2 月 27 日（星期四）的一份研究报告中重申了对 MiMedx Group 的 “增持” 评级，并给出了 13.00 美元的目标价。</p>
<p><strong>查看我们关于 MiMedx Group 的最新股票报告</strong></p>
<h2>MiMedx Group 股票表现</h2>
<p>在周三的交易中，纳斯达克 MDXG 下跌 0.17 美元，报 6.63 美元。该公司股票交易量为 489,764 股，低于其平均交易量 696,177 股。该股票的市值为 9.7704 亿美元，市盈率为 12.05，贝塔值为 1.74。该公司的 50 日移动平均价格为 7.75 美元，200 日移动平均价格为 7.99 美元。MiMedx Group 的 52 周低点为 5.47 美元，52 周高点为 10.14 美元。该公司的债务与股本比率为 0.10，流动比率为 4.10，速动比率为 3.53。</p>
<p>MiMedx Group（纳斯达克代码：MDXG - 获取免费报告）最近在 2 月 26 日（星期三）发布了季度财报。该公司报告每股收益为 0.07 美元，符合市场共识预期的 0.07 美元。MiMedx Group 的净利润率为 23.86%，股本回报率为 26.21%。该公司在本季度的收入为 9291 万美元，而分析师预期为 8942 万美元。卖方分析师预测 MiMedx Group 在当前财年将发布 0.3 美元的每股收益。</p>
<h2>MiMedx Group 内部买卖情况</h2>
<p>在其他新闻中，首席会计官 William Frank Iv Hulse 于 3 月 10 日（星期一）出售了 81,446 股 MiMedx Group 的股票。该股票以平均价格 7.80 美元出售，总交易额为 635,278.80 美元。出售完成后，首席会计官现在持有 494,774 股公司股票，价值约为 3,859,237.20 美元。此交易代表其持股比例下降了 14.13%。该出售在向 SEC 的法律文件中披露，您可以通过此链接访问。此外，内部人士 Kimberly Maersk-Moller 于 3 月 13 日（星期四）出售了 4,106 股该股票。该股票以平均价格 7.89 美元出售，总价值为 32,396.34 美元。交易完成后，内部人士现在持有 310,836 股公司股票，价值为 2,452,496.04 美元。此交易代表其持股比例下降了 1.30%。该出售的披露信息可以在这里找到。在过去的 90 天里，内部人士总共出售了 144,018 股公司股票，价值为 1,130,312 美元。目前，1.30% 的股票由公司内部人士持有。</p>
<h2>MiMedx Group 的机构交易</h2>
<p>几家大型投资者最近买入和卖出了该公司的股票。Paradigm Capital Management Inc. NY 在第四季度增持了 MiMedx Group 的股份，增幅为 0.5%。Paradigm Capital Management Inc. NY 现在持有 4,686,231 股公司股票，价值为 45,082,000 美元，此前在上个季度又购买了 22,131 股。Cannell Capital LLC 在第四季度增持了 MiMedx Group 的股份，增幅为 1.1%。Cannell Capital LLC 现在持有 3,639,545 股公司股票，价值为 35,012,000 美元，此前在上个季度又购买了 40,235 股。First Light Asset Management LLC 在第四季度购买了 MiMedx Group 的新股份，价值为 32,168,000 美元。Geode Capital Management LLC 在第三季度增持了 MiMedx Group 的股份，增幅为 1.6%。Geode Capital Management LLC 现在持有 2,794,358 股公司股票，价值为 16,518,000 美元，此前在上个季度又购买了 44,254 股。最后，Renaissance Technologies LLC 在第四季度增持了 MiMedx Group 的股份，增幅为 18.4%。Renaissance Technologies LLC 现在持有 1,804,557 股公司股票，价值为 17,360,000 美元，此前在此期间又购买了 280,327 股。79.15% 的股票由机构投资者持有。</p>
<h2>MiMedx Group 公司简介</h2>
<p>（获取免费报告）</p>
<p>MiMedx Group, Inc 开发和分销用于各个医疗保健领域的胎盘组织同种异体移植物。它利用其专利和专有的 PURION 工艺处理人类胎盘组织，以生产保留组织固有生物特性和调节蛋白的同种异体移植物。</p>
<h2>进一步阅读</h2>
<ul>
<li>五只我们更看好的股票，胜过 MiMedx Group</li>
<li>ETF 是否支付股息？您需要知道的事项</li>
<li>Viking Therapeutics 股票上涨但难以保持涨幅</li>
<li>三只值得购买和持有的医疗保健股息股票</li>
<li>高通股票刚刚获得新的买入评级——值得期待</li>
<li>顶级生物科技股票：探索创新机会</li>
<li>Meta 股票在分析师下调目标价时仍具上涨潜力</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
<h2>您现在应该投资 1,000 美元在 MiMedx Group 吗？</h2>
<p>在您考虑 MiMedx Group 之前，您需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 MiMedx Group 并不在名单上。</p>
<p>虽然 MiMedx Group 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

MDXG

<p>StockNews.com 将 MiMedx Group (NASDAQ:MDXG) 的评级从 “强力买入” 下调至 “买入”。该股票交易价格下跌至 $6.63，市值为 $9.7704 亿。MiMedx 报告每股收益为 $0.07，符合预期，收入为 $9291 万，超出预测。内部交易活动包括首席会计官 William Hulse 和内部人士 Kimberly Maersk-Moller 的大量出售。机构投资者持有该股票的 79.15%，Paradigm Capital Management 和 Cannell Capital 的持股显著增加</p>

<p>MiMedx Group (NASDAQ:MDXG - Get Free Report) was downgraded by research analysts at StockNews.com from a &#34;strong-buy&#34; rating to a &#34;buy&#34; rating in a note issued to investors on Wednesday.</p>
<div class="lb-trans"><p>MiMedx Group（纳斯达克代码：MDXG - 获取免费报告）在周三发布给投资者的报告中，被 StockNews.com 的研究分析师将评级从 “强力买入” 下调至 “买入”。</p>
</div><p>Separately, Cantor Fitzgerald reissued an &#34;overweight&#34; rating and issued a $13.00 price objective on shares of MiMedx Group in a research note on Thursday, February 27th.</p>
<div class="lb-trans"><p>另外，Cantor Fitzgerald 在 2 月 27 日（星期四）的一份研究报告中重申了对 MiMedx Group 的 “增持” 评级，并给出了 13.00 美元的目标价。</p>
</div><p><strong>Check Out Our Latest Stock Report on MiMedx Group</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 MiMedx Group 的最新股票报告</strong></p>
</div><h2>MiMedx Group Stock Performance</h2>
<div class="lb-trans"><h2>MiMedx Group 股票表现</h2>
</div><p>NASDAQ MDXG traded down $0.17 during trading on Wednesday, reaching $6.63. 489,764 shares of the company's stock were exchanged, compared to its average volume of 696,177. The stock has a market capitalization of $977.04 million, a P/E ratio of 12.05 and a beta of 1.74. The business has a 50 day moving average price of $7.75 and a 200-day moving average price of $7.99. MiMedx Group has a fifty-two week low of $5.47 and a fifty-two week high of $10.14. The company has a debt-to-equity ratio of 0.10, a current ratio of 4.10 and a quick ratio of 3.53.</p>
<div class="lb-trans"><p>在周三的交易中，纳斯达克 MDXG 下跌 0.17 美元，报 6.63 美元。该公司股票交易量为 489,764 股，低于其平均交易量 696,177 股。该股票的市值为 9.7704 亿美元，市盈率为 12.05，贝塔值为 1.74。该公司的 50 日移动平均价格为 7.75 美元，200 日移动平均价格为 7.99 美元。MiMedx Group 的 52 周低点为 5.47 美元，52 周高点为 10.14 美元。该公司的债务与股本比率为 0.10，流动比率为 4.10，速动比率为 3.53。</p>
</div><p>MiMedx Group (NASDAQ:MDXG - Get Free Report) last issued its quarterly earnings data on Wednesday, February 26th. The company reported $0.07 earnings per share for the quarter, hitting the consensus estimate of $0.07. MiMedx Group had a net margin of 23.86% and a return on equity of 26.21%. The business had revenue of $92.91 million during the quarter, compared to analysts' expectations of $89.42 million. Sell-side analysts forecast that MiMedx Group will post 0.3 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>MiMedx Group（纳斯达克代码：MDXG - 获取免费报告）最近在 2 月 26 日（星期三）发布了季度财报。该公司报告每股收益为 0.07 美元，符合市场共识预期的 0.07 美元。MiMedx Group 的净利润率为 23.86%，股本回报率为 26.21%。该公司在本季度的收入为 9291 万美元，而分析师预期为 8942 万美元。卖方分析师预测 MiMedx Group 在当前财年将发布 0.3 美元的每股收益。</p>
</div><h2>Insider Buying and Selling at MiMedx Group</h2>
<div class="lb-trans"><h2>MiMedx Group 内部买卖情况</h2>
</div><p>In other news, CAO William Frank Iv Hulse sold 81,446 shares of MiMedx Group stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $7.80, for a total transaction of $635,278.80. Following the completion of the sale, the chief accounting officer now owns 494,774 shares in the company, valued at approximately $3,859,237.20. This trade represents a 14.13 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Kimberly Maersk-Moller sold 4,106 shares of the stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $7.89, for a total value of $32,396.34. Following the transaction, the insider now owns 310,836 shares in the company, valued at $2,452,496.04. This trade represents a 1.30 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 144,018 shares of company stock worth $1,130,312 over the last ninety days. 1.30% of the stock is currently owned by company insiders.</p>
<div class="lb-trans"><p>在其他新闻中，首席会计官 William Frank Iv Hulse 于 3 月 10 日（星期一）出售了 81,446 股 MiMedx Group 的股票。该股票以平均价格 7.80 美元出售，总交易额为 635,278.80 美元。出售完成后，首席会计官现在持有 494,774 股公司股票，价值约为 3,859,237.20 美元。此交易代表其持股比例下降了 14.13%。该出售在向 SEC 的法律文件中披露，您可以通过此链接访问。此外，内部人士 Kimberly Maersk-Moller 于 3 月 13 日（星期四）出售了 4,106 股该股票。该股票以平均价格 7.89 美元出售，总价值为 32,396.34 美元。交易完成后，内部人士现在持有 310,836 股公司股票，价值为 2,452,496.04 美元。此交易代表其持股比例下降了 1.30%。该出售的披露信息可以在这里找到。在过去的 90 天里，内部人士总共出售了 144,018 股公司股票，价值为 1,130,312 美元。目前，1.30% 的股票由公司内部人士持有。</p>
</div><h2>Institutional Trading of MiMedx Group</h2>
<div class="lb-trans"><h2>MiMedx Group 的机构交易</h2>
</div><p>Several large investors have recently bought and sold shares of the company. Paradigm Capital Management Inc. NY lifted its holdings in shares of MiMedx Group by 0.5% during the fourth quarter. Paradigm Capital Management Inc. NY now owns 4,686,231 shares of the company's stock valued at $45,082,000 after purchasing an additional 22,131 shares in the last quarter. Cannell Capital LLC grew its holdings in MiMedx Group by 1.1% during the 4th quarter. Cannell Capital LLC now owns 3,639,545 shares of the company's stock valued at $35,012,000 after buying an additional 40,235 shares in the last quarter. First Light Asset Management LLC bought a new stake in MiMedx Group in the fourth quarter worth $32,168,000. Geode Capital Management LLC raised its position in shares of MiMedx Group by 1.6% during the 3rd quarter. Geode Capital Management LLC now owns 2,794,358 shares of the company's stock valued at $16,518,000 after buying an additional 44,254 shares in the last quarter. Finally, Renaissance Technologies LLC boosted its holdings in shares of MiMedx Group by 18.4% in the 4th quarter. Renaissance Technologies LLC now owns 1,804,557 shares of the company's stock worth $17,360,000 after purchasing an additional 280,327 shares during the period. 79.15% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>几家大型投资者最近买入和卖出了该公司的股票。Paradigm Capital Management Inc. NY 在第四季度增持了 MiMedx Group 的股份，增幅为 0.5%。Paradigm Capital Management Inc. NY 现在持有 4,686,231 股公司股票，价值为 45,082,000 美元，此前在上个季度又购买了 22,131 股。Cannell Capital LLC 在第四季度增持了 MiMedx Group 的股份，增幅为 1.1%。Cannell Capital LLC 现在持有 3,639,545 股公司股票，价值为 35,012,000 美元，此前在上个季度又购买了 40,235 股。First Light Asset Management LLC 在第四季度购买了 MiMedx Group 的新股份，价值为 32,168,000 美元。Geode Capital Management LLC 在第三季度增持了 MiMedx Group 的股份，增幅为 1.6%。Geode Capital Management LLC 现在持有 2,794,358 股公司股票，价值为 16,518,000 美元，此前在上个季度又购买了 44,254 股。最后，Renaissance Technologies LLC 在第四季度增持了 MiMedx Group 的股份，增幅为 18.4%。Renaissance Technologies LLC 现在持有 1,804,557 股公司股票，价值为 17,360,000 美元，此前在此期间又购买了 280,327 股。79.15% 的股票由机构投资者持有。</p>
</div><h2>MiMedx Group Company Profile</h2>
<div class="lb-trans"><h2>MiMedx Group 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.</p>
<div class="lb-trans"><p>MiMedx Group, Inc 开发和分销用于各个医疗保健领域的胎盘组织同种异体移植物。它利用其专利和专有的 PURION 工艺处理人类胎盘组织，以生产保留组织固有生物特性和调节蛋白的同种异体移植物。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than MiMedx Group</li>
<li>Do ETFs Pay Dividends? What You Need to Know</li>
<li>Viking Therapeutics Stock Pops But Struggles to Hold Gains</li>
<li>The Top 3 Healthcare Dividend Stocks to Buy and Hold</li>
<li>Qualcomm Stock Just Earned a Fresh Buy Rating—Get Excited</li>
<li>Top Biotech Stocks: Exploring Innovation Opportunities</li>
<li>Meta Stock Holds Upside Potential as Analysts Cut Price Targets</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 MiMedx Group</li>
<li>ETF 是否支付股息？您需要知道的事项</li>
<li>Viking Therapeutics 股票上涨但难以保持涨幅</li>
<li>三只值得购买和持有的医疗保健股息股票</li>
<li>高通股票刚刚获得新的买入评级——值得期待</li>
<li>顶级生物科技股票：探索创新机会</li>
<li>Meta 股票在分析师下调目标价时仍具上涨潜力</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in MiMedx Group Right Now?</h2>
<div class="lb-trans"><h2>您现在应该投资 1,000 美元在 MiMedx Group 吗？</h2>
</div><p>Before you consider MiMedx Group, you'll want to hear this.</p>
<div class="lb-trans"><p>在您考虑 MiMedx Group 之前，您需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MiMedx Group wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 MiMedx Group 并不在名单上。</p>
</div><p>While MiMedx Group currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 MiMedx Group 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

StockNews.com 将 MiMedx Group（NASDAQ:MDXG）的评级下调至买入